What changed today in Regulatory: 1 new study

Why this matters

Federal Register documents and FDA notices can change compliance obligations, deadlines and enforcement priorities for pharmacies, compounders and prescribers.

What changed

1. New research in Journal of obesity & metabolic syndrome: “The Future of Metabolic and Bariatric Surgery in the Glucagon-Like Peptide-1 Era: Has the Scalpel Become Obsolete?”.[1]
2. Also reported by Pharmacy Times: “The Coding Gap Nobody Prices In: Why New Specialty Drugs Launch Reimbursement-Blind”.[2]

Who this affects

• Pharmacies
• 503A compounders
• 503B outsourcing facilities
• Pharmacists
• Prescribers
• Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

Source file

1. [1]
   The Future of Metabolic and Bariatric Surgery in the Glucagon-Like Peptide-1 Era: Has the Scalpel Become Obsolete? (opens the source in a new tab)

   Peer reviewedJournal of obesity & metabolic syndromeOct 7, 2026

2. [2]
   The Coding Gap Nobody Prices In: Why New Specialty Drugs Launch Reimbursement-Blind (opens the source in a new tab)

   News reportingPharmacy TimesOct 8, 2026Industry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.